Australian Clinical Labs Limited (ASX:ACL) insider Mark Haberlin bought 22,500 shares of the company’s stock in a transaction on Monday, November 22nd. The stock was bought at an average cost of A$4.40 ($3.14) per share, for a total transaction of A$98,977.50 ($70,698.21).
The company has a debt-to-equity ratio of 359.23, a quick ratio of 0.60 and a current ratio of 0.71.
Australian Clinical Labs Company Profile
Recommended Story: Discover Your Risk Tolerance
Receive News & Ratings for Australian Clinical Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Australian Clinical Labs and related companies with MarketBeat.com's FREE daily email newsletter.